Search Results - "Poms, Abby D."

Five-Year Outcomes of Patients Enrolled in the REVEAL Registry by Farber, Harrison W., MD, FCCP, Miller, Dave P., MS, Poms, Abby D., BS, RRT, Badesch, David B., MD, FCCP, Frost, Adaani E., MD, Rouzic, Erwan Muros-Le, MPH, Romero, Alain J., PharmD, PhD, Benton, Wade W., PharmD, Elliott, C. Gregory, MD, McGoon, Michael D., MD, FCCP, Benza, Raymond L., MD

“…BACKGROUND Pulmonary arterial hypertension (PAH) is a rare, severe disease characterized by worsening right-sided heart failure, decreasing functional status,…”
Get full text

Comprehensive Assessment of Right Ventricular Function in Patients with Pulmonary Hypertension with Global Longitudinal Peak Systolic Strain Derived from Multiple Right Ventricular Views by Rajagopal, Sudarshan, MD, PhD, Forsha, Daniel E., MD, Risum, Niels, MD, PhD, Hornik, Christoph P., MD, Poms, Abby D., RRT, Fortin, Terry A., MD, Tapson, Victor F., MD, Velazquez, Eric J., MD, Kisslo, Joseph, MD, Samad, Zainab, MD

“…Background Right ventricular (RV) function is a strong predictor of mortality in pulmonary hypertension (PH), but two-dimensional (2D) echocardiography–derived…”
Get full text

United States Pulmonary Hypertension Scientific Registry (USPHSR): rationale, design, and clinical implications by Elliott, C. Gregory, Austin, Eric D., Badesch, David, Badlam, Jessica, Benza, Raymond L., Chung, Wendy K., Farber, Harrison W., Feldkircher, Kathy, Frost, Adaani E., Poms, Abby D., Lutz, Katie A., Pauciulo, Michael W., Yu, Chang, Nichols, William C.

“…Diagnostic World Health Organization (WHO) Group 1 pulmonary arterial hypertension (PAH) and Diagnostic Group 1' pulmonary veno-occlusive disease (PVOD) and/or…”
Get full text

Comorbid conditions and outcomes in patients with pulmonary arterial hypertension: a REVEAL registry analysis by Poms, Abby D, Turner, Michelle, Farber, Harrison W, Meltzer, Leslie A, McGoon, Michael D

“…Comorbidities can affect disease progression and/or response to treatment in various conditions. Comorbid conditions are prevalent in patients with pulmonary…”
Get full text

United States Pulmonary Hypertension Scientific Registry: Baseline Characteristics by Badlam, Jessica B, Badesch, David B, Austin, Eric D, Benza, Raymond L, Chung, Wendy K, Farber, Harrison W, Feldkircher, Kathy, Frost, Adaani E, Poms, Abby D, Lutz, Katie A, Pauciulo, Michael W, Yu, Chang, Nichols, William C, Elliott, C Gregory

“…The treatment, genotyping, and phenotyping of patients with World Health Organization Group 1 pulmonary arterial hypertension (PAH) have evolved dramatically…”
Get full text

Safety and Tolerability of High-dose Inhaled Treprostinil in Pulmonary Hypertension by Parikh, Kishan S, Rajagopal, Sudarshan, Fortin, Terry, Tapson, Victor F, Poms, Abby D

“…Pulmonary arterial hypertension (PAH) has emerging therapeutic options including prostacyclin analogs. Inhaled therapy offers advantages compared with…”
Get full text

Comorbid Conditions and Outcomes in Patients With Pulmonary Arterial Hypertension by Poms, Abby D., BS, RRT, Turner, Michelle, MS, Farber, Harrison W., MD, FCCP, Meltzer, Leslie A., PhD, McGoon, Michael D., MD, FCCP

“…Background Comorbidities can affect disease progression and/or response to treatment in various conditions. Comorbid conditions are prevalent in patients with…”
Get full text

United States Pulmonary Hypertension Scientific Registry by Badlam, Jessica B., Badesch, David B., Austin, Eric D., Benza, Raymond L., Chung, Wendy K., Farber, Harrison W., Feldkircher, Kathy, Frost, Adaani E., Poms, Abby D., Lutz, Katie A., Pauciulo, Michael W., Yu, Chang, Nichols, William C., Elliott, C. Gregory, Simms, Robert, Fortin, Terry, Safdar, Zeenat, Burger, Charles D., Frantz, Robert P., Hill, Nicholas S., Airhart, Sophia, Elwing, Jean, Simon, Marc, White, R. James, Robbins, Ivan M., Chakinala, Murali M.

“…The treatment, genotyping, and phenotyping of patients with World Health Organization Group 1 pulmonary arterial hypertension (PAH) have evolved dramatically…”
Get full text